The role Navigator Medicines is building an immunology-first biotech focused on bispecific drug discovery for immunology and inflammatory diseases. This role exists because the success of our programs depends on clear immunological strategy, strong discovery execution, and high-quality decision-making from target identification through IND. As Senior Director of Immunology , you will shape and execute discovery strategy across bispecific programs, working in a highly matrixed environment. You will balance deep immunology and drug discovery expertise with the ability to communicate clearly, collaborate broadly, and influence scientific direction at the company level. This is a role for someone who wants real ownership of discovery programs—not just functional oversight.
The problems you'll work on
- Defining and executing immunology discovery strategies that integrate biology, emerging technologies, and therapeutic opportunity
- Owning programs end-to-end, from target identification through IND-enabling studies, with accountability for scientific quality and progression decisions
- Interpreting complex preclinical data to inform go/no‑go decisions, risk assessment, and program prioritization
What you'll learn
- How bispecific immunology programs are built, challenged, and advanced inside a platform-driven biotech
- How early mechanistic hypotheses translate—or fail—under preclinical, regulatory, and IND-readiness constraints
- How senior scientific leaders balance rigor, speed, and external partnership inputs in real‑world development timelines
How we work
- Programs run in a matrixed model, requiring strong collaboration across biology, translational science, platform, and leadership
- External partners matter: CROs, academics, and advisors are treated as extensions of the team, not vendors
- Strategy is debated openly, decisions are owned, and communication with senior leaders and advisors is direct and data-driven
What you bring
- PhD in Immunology, Pharmacology, or a related discipline, with significant industry experience advancing programs from discovery toward IND
- Deep understanding of preclinical development, including GLP, ICH guidance, and FDA expectations for IND-enabling work
- Strong scientific judgment, communication skills, and the ability to influence across scientific, regulatory, and business stakeholders
About Navigator Medicines
Navigator Medicines is a clinical‑stage biopharmaceutical company dedicated to advancing biologics for targeted immune regulation and restoration. Founded in 2024 as a subsidiary of Sera Medicines with $100M Series A financing co‑led by RA Capital Management and Forbion, the company focuses on developing innovative therapies for complex autoimmune diseases. Navigator Medicines is committed to improving the lives of patients with heterogeneous conditions through cutting‑edge science and groundbreaking advancements in immune therapeutics.
Legal & Equal Opportunity Notice
Navigator Medicines is an equal opportunity employer and provides reasonable accommodations as required by Massachusetts and California law.
#J-18808-Ljbffr